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Purity of transferred CD8+ T cells is crucial for safety
and efﬁcacy of combinatorial tumor immunotherapy in
the absence of SHP-1
H Angharad Watson1, Garry Dolton1, Julia Ohme1, Kristin Ladell1, Miriam Vigar1, Sophie Wehenkel1,
James Hindley1, Rebar N Mohammed1, Kelly Miners1, Rhys A Luckwell1, David A Price1,2, R James Matthews1,3
and Ann Ager1,3
Adoptive transfer of tumor-speciﬁc cytotoxic T cells is a promising advance in cancer therapy. Similarly, checkpoint inhibition
has shown striking clinical results in some patients. Here we combine adoptive cell transfer with ablation of the checkpoint
protein Src homology 2-domain-containing phosphatase 1 (SHP-1, Ptpn6). Naturally occurring motheaten mice lack SHP-1 and
do not survive weaning due to extensive immunopathology. To circumvent this limitation, we created a novel SHP-1null mouse
that is viable up to 12 weeks of age by knocking out IL1r1. Using this model, we demonstrate that the absence of SHP-1
augments the ability of adoptively transferred CD8+ T cells to control tumor growth. This therapeutic effect was only observed
in situations where T-cell numbers were limited, analogous to clinical settings. However, adoptive transfer of non-CD8+ SHP-1null
hematopoietic cells resulted in lethal motheaten-like pathology, indicating that systemic inhibition of SHP-1 could have serious
adverse effects. Despite this caveat, our ﬁndings support the development of SHP-1 inhibition strategies in human T cells to
complement adoptive transfer therapies in the clinic.
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The advent of checkpoint inhibitors has proven to be an exciting
development in the ﬁght against cancer. Monoclonal antibodies
directed against CTLA-4 (ipilimumab) and PD-1 (nivolumab,
pembrolizumab) act via the blockade of key molecular interactions
that are known to inhibit T-cell expansion, activation and/or
cytoxicity.1,2 These biologic agents are not successful in all patients,
although combining anti-CTLA-4 and anti-PD-1 leads to improved
outcomes compared with either therapy alone.3 This synergistic effect
suggests that other inhibitory molecules could be targeted similarly,
either singly or in combination, to provide additional beneﬁts. Src
homology 2-domain-containing phosphatase 1 (SHP-1, Ptpn6) is an
inhibitory enzyme expressed at high levels in all hematopoietic cell
lineages and at all stages of maturity.4,5 In T cells, SHP-1 regulates
interactions with antigen-presenting cells where we have demonstrated
its involvement in setting activation thresholds during thymic selection
and reducing the requirement for CD28 costimulation.6,7
SHP-1 expression in tumors has been the subject of much
investigation. A number of currently available cancer drugs may kill
tumor cells by activating SHP-1, leading to inhibition of STAT3 and
cell death by apoptosis.8 Conversely, immunotherapies have focused
on ablation of SHP-1 to counter its inhibitory action on cytotoxic
T cells.9 The clinically available active-site SHP-1 inhibitor sodium
stibogluconate, which also targets the related phosphatase SHP-2, is
currently being investigated as a potential cancer therapeutic.10
A number of other small molecule protein tyrosine phosphatase
inhibitors are being investigated as cancer therapeutics. However, none
of them are speciﬁc for SHP-1,10–14 and the systemic administration of
a multiple phosphatase inhibitor risks off-target effects. Indeed, we
show here that the absence of SHP-1 in non-CD8+ hematopoietic cells
is responsible for fatal lung pathology. Targeting a speciﬁc cell type
through genetic manipulation reduces such risks to patient safety.
Here we demonstrate the improved ability of SHP-1-deﬁcient T cells
to limit tumor colonization of the lungs and control the growth of
solid tumors in comparison with T cells expressing SHP-1.
RESULTS AND DISCUSSION
Introduction of IL1r1− /− does not affect the anti-tumor properties
of SHP-1null T cells
To ensure that SHP-1null and wild type (WT) SHP-1-sufﬁcient cells
expressed equivalent levels of an identical T-cell receptor (TCR), we
used the transgenic F5 mouse, in which more than 90% of CD8+
T cells express a TCR speciﬁc for the internal inﬂuenza nucleoprotein
antigen NP68.15 In addition, we engineered a B16F10 murine
melanoma cell line to express the NP68 peptide fused with green
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ﬂuorescent protein (GFP) as well as a luciferase reporter gene. These
cells will be referred to as NP68-B16. The B16 tumor line is poorly
immunogenic, and mice with polyclonal TCRs were unable to control
the growth of subcutaneously grafted NP68-B16 cells, in contrast to F5
mice (Figures 1a and b). Similarly, adoptive transfer of F5 CD8+ cells,
but not polyclonal CD8+ T cells, controlled tumor growth (Figure 1b).
The naturally occurring motheaten (me) mouse is null for SHP-1.
However, the absence of SHP-1 across all lineages produces severe
pathology, and mice homozygous for the me locus (me/me) die before
weaning, mainly as a result of lung pathology.16 We employed an assay
referred to as a metastatic model, in which tumor cells are introduced
intravenously, causing metastasis-like colonization of the lungs with-
out a primary solid tumor. Mice treated prophylactically with me/me
CD8+ T cells developed signiﬁcantly fewer metastatic tumor nodules
in the lung than mice treated with the corresponding WT cells
(Figure 1c). However, limited numbers of me/me T cells are available
for transfer in this model due to the severe pathology of me/me mice.
There is convincing evidence that the severe cutaneous pathology
observed in me/me mice is largely myeloid-driven and reliant on
signaling via interleukin 1 (IL1).17 An IL1r1 knockout was therefore
crossed with the me/me line homozygous for the F5 TCR. The
F5+/+IL1r1− /−me/me mice, hereafter called SHP-1null, survived up to
12 weeks of age, exceeding the life expectancy of even the motheaten
viable strain.18 Skin and lung pathology was still detectable in these
animals, but was highly attenuated. However, despite the attenuated
pathology, birth rates of the SHP-1null mice were signiﬁcantly lower
than expected (P⩽ 0.005) at only 15 from 130 pups being
homozygous motheaten from matings of F5+/+ IL1r1− /−me/me mice.
In addition, ~ 30% of all pups died before weaning, suggesting
developmentally related pathology.
To establish that tumor prophylaxis mediated by me/me CD8+
T cells was maintained in the absence of IL1 signaling, the metastasis
experiment was repeated using magnetically isolated SHP-1null naive
CD8+ T cells versus naive CD8+ T cells from their SHP-1-sufﬁcient
IL1r1− /− littermates (SHP-1WT). SHP-1null CD8+ T cells maintained a
superior ability to prevent tumor nodule formation compared with
their SHP-1WT counterparts (Figure 1d), similar to the results using
IL1r1-sufﬁcient cells.
To demonstrate the therapeutic potential of SHP-1null CD8+ T cells,
NP68-B16 cells were introduced subcutaneously into host mice in a
solid tumor model (Figure 2a). Tumors were established for 7 days
and then treated with 4.5 × 105 magnetically sorted CD8+ T cells. Both
SHP-1WT CD8+ T cells and SHP-1null CD8+ T cells signiﬁcantly
controlled tumor growth (Figure 2b), however, SHP-1WT cells were
more effective. At day 17, SHP-1WT CD8+ T cells caused tumor
regression in all mice. In contrast, no regression was observed among
mice treated with SHP-1null CD8+ T cells. This observation suggests
that the absence of SHP-1 offers no beneﬁt in the treatment of tumors
at this T cell dose (high dose) of cells. When the cell dose was reduced
to 5× 104 CD8+ T cells per mouse (low dose), only SHP-1null cells
were able control tumor growth (Figure 2c).
A unique SHP-1null population transplants me/me pathology
to tumor-bearing hosts
There was a marked weight loss and declining health among the
animals treated with high-dose SHP-1null cells, necessitating euthanasia
by day 31. Post-mortem analysis revealed considerable lung pathology,
not seen in the lung tumor model, but known to be a feature of the
motheaten mouse. Analysis of the donor cells revealed that despite
magnetic enrichment of CD8+ cells before transfer, a large population
of CD8− live cells persisted in the high-dose SHP-1null donor cells, and
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Figure 1 CD8+ T cells lacking SHP-1 prevent tumor metastasis formation. (a) 5×105 B16-NP68 cells were injected subcutaneously into F5B6 hosts or hosts
with polyclonal TCRs (C57BL/6) (n=3–5). Differences in tumor growth rate were calculated by linear regression. ***P⩽0.001. (b) C57BL/6 mice
received B16-NP68 tumor cells as before. Seven days after tumor injections, mice were sublethally irradiated and given NP68 peptide in IFA with or without
2.25×105 naive CD8+ T cells (n=7). Tumor growth rates were compared using linear regression. ***P⩽0.001. (c) Tumor nodule enumeration following
treatment with F5me/me or F5WT CD8+ T cells. One point= one mouse. Signiﬁcance was calculated using one-way ANOVA with Tukey’s post hoc test.
***P⩽0.001. (d) Tumor nodule enumeration following treatment with SHP-1null or SHP-1WT CD8+ T cells. Signiﬁcance was calculated using one-way
ANOVA and Tukey’s post hoc test.
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to a lesser extent in the low-dose SHP-1null, which was not present in
the SHP-1WT donor cells (Figure 3a).
Histological analysis of the lungs revealed marked ﬁbrosis, leukocyte
inﬁltration and evidence of hemorrhage (Prussian Blue staining
indicates hemosiderin, generally macrophage-associated) in the lungs
of mice receiving high-dose SHP-1null cells (Figure 3b). Luciferase was
also detected in the lungs of high-dose SHP-1null cell recipients,
suggesting the presence of NP68-B16 tumor cells (Figure 3d). In
contrast, mice receiving either no T cells or SHP-1WT cells had
histologically healthy lungs, excluding a role for radiation in the
observed pathology. Mice receiving low-dose SHP-1null cells with a
lower proportion of contaminating cells exhibited less pathology
(Figure 3c, upper panel). Moreover, transfer of a low dose of the
contaminating CD8− cells alone, isolated by ﬂow sorting of
magnetically enriched cells (Figure 3c, lower panel), caused ﬁbrosis
and leukocyte inﬁltration comparable to the high-dose SHP-1null cells,
indicating that it is not the cell dose, but the presence of this
contaminating population that is pathological. These ﬁndings concur
with the current understanding of me/me lung pathology being CD8+
T-cell-independent.19,20
Detailed analysis of the magnetically enriched cell population by
ﬂow cytometry indicated the presence of B cells (CD19+), natural
killer cells (NK1.1+), and both lymphoid and myeloid dendritic cells
(CD11c+ and either CD8+ or CD11b+, respectively) in the transferred
SHP-1null cells (Supplementary Fig. 1). Smaller populations of
monocytes and macrophages were also detected (CD11b+, Ly6G−,
Ly6C+/− ). Any of these contaminating subsets, either alone or in
combination, could be responsible for the observed pathology.17–19
It remains unclear how such diverse cell populations escaped
capture by isolation kits incorporating antibodies speciﬁc for a number
of markers detected in subsequent ﬂow cytometry experiments,
including CD11b, CD11c, CD19 and MHC-class II. However, this
phenomenon appears linked in some way to the absence of SHP-1 in
hematopoietic cell lineages.
Puriﬁed CD8+ SHP-1null T cells control tumors without pathology
To eliminate contamination, magnetically enriched CD8+ cells were
further sorted by ﬂow cytometry. Naive CD8+ T cells were 498%
pure (Figure 4a). These cells were transferred at low dose to
tumor-bearing hosts 7 days after subcutaneous injection of tumor
cells. The puriﬁed SHP-1null CD8+ cells still offered improved control
of tumor growth (Figure 4b), although more modestly than the less-
pure cell population (Figure 2c), indicating that the contaminating
cells were anti-tumoral as well as pathological. Me/me-like lung
pathology was not observed in any of the hosts (Figure 4c) and
luminescent tumor cells were not detected in the lungs (Figure 4d).
These data show that relief of SHP-1-mediated T-cell inhibition is a
feasible strategy to improve the success rates of adoptive T-cell transfer
5x105
B16-NP68 
s.c.
Day 7
Irradiation
4.5x105 naïve CD8+ i.v.
Peptide IFA
Day 0
Humane 
Endpoints
Days Post Tumor Injection
Tu
m
or
 s
iz
e 
m
m
2
0 20 40 60
0
50
100
150
200 No Transfer
SHP-1null
SHP-1WT
*** ***
Days Post Tumor Injection
Tu
m
or
 s
iz
e 
m
m
2
0 5 10 15 20 25
0
20
40
60
80
No Transfer
SHP-1
SHP-1
Tu
m
or
 s
iz
e 
m
m
2
0 10 20 30
0
50
100
150
200
SHP-1WT
SHP-1null
No Transfer
***
Days Post Tumor Injection
High Dose
Low Dose
Figure 2 SHP-1null cells only offer improved tumor control at low cell doses. (a) Schematic representation of therapeutic solid tumor model. (b) Tumor growth
curves for C57BL/6 hosts treated with 4.5×105 SHP-1null or SHP-1WT CD8+ T cells (n=9–11). Expanded section shows early stage growth, up to day 23, in
more detail. Differences in tumor growth rate were calculated by linear regression. ***P⩽0.001. (c) Tumor growth curves for tumor-bearing hosts treated with
5×104 SHP-1null or SHP-1WT CD8+ T cells (n=6–8). Differences in tumor growth rate were calculated by linear regression. ***P⩽0.001.
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therapy, supporting previous investigations using a disseminated
leukemia model.9 Our earlier work indicated that one mechanism
by which SHP-1 deletion suppresses tumor growth is through
increased expansion of effector T cells.7,21 In the present study, we
observed a 415-fold expansion of SHP-1null T cells relative to
SHP-1WT T cells in tumor-draining lymph nodes 7 days after transfer
into a tumor-bearing host (data not shown). Furthermore, histological
analysis of tumor tissue recovered from the experiment shown in
Figure 4b revealed signiﬁcantly increased numbers of T cells in those
tumors that were treated with SHP-1null T cells (Figure 4e). The cell
dose-dependent action of SHP-1 inhibition in this system also suggests
that increased proliferation is important, and is an appealing aspect of
this strategy given that tumor-speciﬁc T cells are a limited resource in
the clinic. If this strategy was translated to the clinic, contamination
by other SHP-1null lineages would be unlikely in adoptive transfer
strategies, as only CD8+ T cells would be manipulated for transfer.
However, the pathology associated with transfer of non-CD8+
SHP-1null lineages revealed in this study is an important consideration
for systemic inhibitor-based strategies, which would result in SHP-1
inhibition across multiple cell types.
It should be noted that the anti-viral F5 TCR operates at a higher
afﬁnity than tumor-speciﬁc TCRs.22 The effect of SHP-1 inhibition
may therefore be more pronounced in the clinic due to a greater
impact on activation thresholds at suboptimal TCR afﬁnities.
Furthermore, the B16 melanoma line is poorly immunogenic and
cannot be controlled with anti-CTLA-4 therapy alone.23 These
considerations further suggest that the modest control of B16 growth
demonstrated here may translate to more profound effects in humans.
The question of how other checkpoint inhibitors might interact
with SHP-1 inhibition strategies is an important one. A recent study
demonstrated a broad role for SHP-1 in the regulation of CD8+ T cells
with a range of TCR afﬁnities, whereas PD-1 is preferentially expressed
alongside higher afﬁnity TCRs.24 In addition, the interaction between
SHP-1 and CTLA-4 is limited.25 These ﬁndings suggest that combin-
ing SHP-1 inhibition with PD-1 blockade would be more likely to
result in synergy than redundancy. SHP-1 modulates the activity of
several proteins that become activated following TCR engagement,
including CD3ζ, lymphocyte-speciﬁc protein tyrosine kinase (Lck),
ζ-chain-associated protein kinase 70 (ZAP70), phosphoinositide 3
kinase (PI3K) and the ‘onc F’ proto-oncogene (Vav1), and is known to
bind the inhibitory leukocyte-associated immunoglobulin-like
receptor-1 (LAIR-1).21,26–31 The genetic model used here supports
the development of translational approaches, such as genome editing
using CRISPR or TALENs,32–35 to manipulate SHP-1 expression in
human T cells to augment cancer immunotherapy.
METHODS
Mice
Motheaten heterozygous (C57BL/6J me+/− ) mice were obtained from the
Jackson Laboratory, and the transgenic F5 TCR was introduced as described
previously.15 F5+/+ me+/− mice were then crossed with IL1r1− /− mice
(B6.126S7-IL1r1tm1Imx/J). Genotyping was performed as described previously
Lu
m
in
es
ce
nc
e 
U
ni
ts
No Transfer SHP-1WT SHP-1null
0
200
400
600
800
1000
SHP-1WT SHP-1null
H
ig
h 
D
os
e
Lo
w
 D
os
e
CD8
95.9% 55.6%
83.2%
H&E Prussian Blue
N
o 
Tr
an
sf
er
SH
P-
1W
T
SH
P-
1n
ul
l
High Dose
SH
P-
1n
ul
l
C
D
8-
SH
P-
1n
ul
l
H&E Prussian Blue
Low Dose
Figure 3 Contaminating CD8− cells from SHP-1null donors causes fatal lung pathology. (a) Flow cytometric analysis of CD8-stained, magnetically enriched
donor cells used in ‘high dose’ (Figure 2b) or ‘low dose’ (Figure 2c). Gray peak represents ﬂuorescence minus CD8 antibody. (b) Lungs from hosts receiving
high cell doses. Sections were stained with H&E or Prussian Blue. Images were acquired at × 20 magniﬁcation. (c) Lungs from hosts receiving low cell
doses. Sections were stained with H&E or Prussian Blue. Black arrows indicate alveolar septa, green arrows indicate ﬁbrosis, orange arrows indicate
hemosiderin. Images were acquired at ×20 magniﬁcation. (d) Luciferase expression measured in lung lysates from hosts receiving high cell doses.
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for F5 and me,15 and following standard JAX protocols for IL1r1
(http://jaxmice.jax.org/strain/003245.html). Mice were bred to homozygosity
for F5 and IL1r1 knockout, and F5+/+IL1r1− /−me+/− were bred to produce F5
+/+IL1r1− /−me− /− offspring (SHP-1null). CD8+ cells were isolated from these
mice and their WT littermates (SHP-1WT, conﬁrmed by PCR) at 8–12 weeks of
age. Eight-to-nine-week-old C57BL/6J tumor host mice were purchased from
Charles River. Hosts and T-cell donors were gender-matched. Mice had free
access to food and water, and were housed and maintained according to Home
Ofﬁce standards and the Animals (Scientiﬁc Procedures) Act 1986.
Adoptive cell transfer
CD8+ T cells were enriched from splenocytes by negative selection using a
CD8a+ T-cell isolation kit with LS columns, according to the manufacturer’s
instructions (Miltenyi Biotec Ltd, Bisley, Surrey, UK). Isolated cells were frozen
until required. Thawed cells were recovered at 37 °C for a minimum of 4 h, and
either used directly or further puriﬁed by ﬂow sorting, as indicated. Flow-sorted
cells were stained with anti-TCR-FITC, anti-CD4-PE, anti-CD8-APC, anti-
CD11c-PE, anti-CD19PECy7, anti-CD27-BV421 and anti-CD44-APCCy7
(BioLegend, London, UK). Dead cells were excluded using Zombie Aqua
(eBioscience Ltd, Hatﬁeld, UK). Cells were sorted using a custom-modiﬁed
FACSAria II ﬂow cytometer (BD Biosciences, 9320 Erembodegem, Belgium).
Voltages were set using OneComp eBeads (eBioscience) and Arc-reactive beads
(Invitrogen, Life Technologies Ltd, Paisley, UK). The ﬂow-sorted naive CD8+
fraction was deﬁned as live single cells with the following phenotype: TCR+,
CD4−, CD8+, CD11c−, CD19−, CD27+, CD44−. Cells that were positive for
CD4, CD11c and CD19 were sorted into the CD8− fraction. CD8+ cells that
were positive for CD44 or negative/dim for CD27 were discarded. Cells were
counted using a hemocytometer and resuspended in PBS for injection.
Flow cytometry
Cells were stained with LIVE/DEAD Fixable Aqua (Invitrogen), treated with
50 nM dasatinib (Sigma-Aldrich Co Ltd, Dorset, UK) to prevent TCR down-
regulation, then stained with PE-conjugated NP68 tetramer at 37 °C, followed
by surface antibodies at 4 °C as follows: anti-TCRVβ11-FITC, anti-CD8-
PerCPCy5.5, anti-CD27-BV421, anti-CD44-APCCy7, anti-CD62L-PECy7 and
anti-CD69-APC (BioLegend). Cells were ﬁxed and analyzed using a FACSCanto
%
 C
D
3 
C
el
ls
 b
y 
A
re
a
SHP-1WT CD8+ SHP-1null CD8+
0
2
4
6
8
**
Tu
m
or
 s
iz
e 
m
m
2
0 10 20 30
0
50
100
150
200
SHP-1WT CD8+
SHP-1null CD8+
No Transfer
*
Days Post Tumor Injection
SH
P-
1W
T
SH
P-
1n
ul
l
N
o 
Tr
an
sf
er
H&E Prussian Blue
Lu
m
in
es
ce
nc
e 
U
ni
ts
No Transfer SHP-1WT SHP-1null
0
50
100
150
200
SHP-1WT SHP-1null
CD8
98.9% 99.0%
Figure 4 Flow-sorted SHP-1null naive CD8+ T cells control tumor growth without lung pathology. (a) Flow cytometric analysis of magnetically enriched and
ﬂow-sorted donor cells. (b) Tumor growth curves for hosts treated with low dose, enriched/sorted SHP-1null or SHP-1WT CD8+ T cells (n=8–9). ‘No transfer’
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*P⩽0.05. (c) H&E and Prussian Blue staining of lungs from tumor-bearing hosts shown in b. (d) Luciferase expression measured in lung lysates from hosts
shown in b. (e) Quantiﬁcation of CD3 staining in tumor sections taken from Figure 4c. One dot= one ﬁeld of view (5 ﬁelds of view per tumor). Signiﬁcance
was calculated using a two-tailed unpaired Student’s t-test. **P⩽0.01.
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II ﬂow cytometer (BD Biosciences). Voltages were set using OneComp eBeads
(eBioscience) and Arc-reactive beads (Invitrogen). CytoCount beads were used
to quantify cell numbers, according to the manufacturer’s instructions (Dako
UK Ltd, Ely, UK).
Tumor cell line
The murine melanoma cell line B16F10 (ATCC number CRL-6475) was
transduced via retroviral infection in the presence of 10 μg ml− 1 protamine
sulfate (Sigma) to express luciferase and a YFP reporter (separated by an IRES).
Two rounds of infection were performed, and YFP+ cells were identiﬁed using a
FACSCalibur ﬂow cytometer (BD Biosciences). YFP+ cells were cloned and
assayed for luciferase activity. A monoclonal luciferase+ line was then
super-infected with a retrovirus encoding the class I-restricted inﬂuenza
nucleoprotein epitope NP68 as a fusion protein with GFP.36 These cells were
sorted by ﬂow cytometry as described above and cloned. All experiments were
performed using a single mycoplasma-free line of monoclonal luciferase+ NP68
+ B16F10 cells, designated NP68-B16.
Luciferase quantiﬁcation in lungs
The left lung node was collected in PBS, and homogenized to a single-cell
suspension. Cells were lysed with passive lysis buffer (Promega UK, South-
ampton, UK), and the lysate was stored at − 20 °C until required. All lysates for
a single experiment were assayed together in triplicate. Luciferase activity was
quantiﬁed in vitro using a Dual-Luciferase Reporter Assay (Promega) and
measured using a FLUOstar OPTIMA (BMG Labtech Ltd, Aylesbury, UK).
Tumor metastasis model
C57BL/6J mice were exposed to 650 cGy total body irradiation (TBI) on day 1.
On day 2, 3.4 × 104 naive T cells were transferred intravenously, followed by
subcutaneous administration of 100 μg NP68 peptide (ASNENMDAM, Peptide
Synthetics) in incomplete Freund’s adjuvant (peptide IFA, ﬁnal volume of
200 μl). The next day, 2.5 × 106 NP68-B16 tumor cells were transferred
intravenously. Mice were monitored until day 13 or 14 and then killed. The
lungs were excised and ﬁxed in 4% formalin. Tumor metastasis nodules were
enumerated macroscopically up to a maximum detection limit of 425 nodules.
Solid tumor model
NP68-B16 cells (5× 105) were injected subcutaneously into the shaven left
ﬂank. Tumors were measured with callipers, and tumor size was calculated as
the product of two perpendicular diameters. On day 7, tumor-bearing hosts
were irradiated with 650 cGy TBI and then treated with peptide IFA and naive
T cells, at either a high dose of 4.5 × 105 cells per mouse or a low dose of 5× 104
cells per mouse, unless stated otherwise.
Immunohistochemistry
Formalin-ﬁxed parafﬁn-embedded lung tissue was cut into 5-μm sections and
stained with either hematoxylin and eosin (H&E, Sigma) or Prussian Blue using
standard histological techniques. Prussian Blue staining was performed after
rehydration using freshly prepared 2% potassium ferrocyanide (Sigma) and 2%
hydrochloric acid (Fisher Chemical, Loughborough, UK). One hour later,
sections were rinsed several times in distilled water, counterstained with neutral
red (Sigma), dehydrated and mounted with DPX (Fisher Chemical). Images
were taken using an Axio microscope with AxioVision software (Zeiss).
Formalin-ﬁxed parafﬁn-embedded tumor tissue was cut into 5-μm sections
and rehydrated. Antigen retrieval was performed using Tris-EDTA buffer
(10 mM Tris, 1 mM EDTA, pH 9). Sections were blocked with 0.5% H2O2
in methanol, followed by goat serum (ImmPRESS Reagent Kit, Vector
Laboratories, Peterborough, UK). After staining with rat anti-CD31 (DIA-310,
Dianova) and goat anti-rat linked to horseradish peroxidise (HRP; Vector
Laboratories Ltd), sections were developed for 30 s with 3,3′-diaminobenzidine
(DAB). Slides were then rinsed in PBS, blocked with horse serum (Vector
Laboratories) and stained overnight with rabbit anti-CD3 (A0452, Dako). After
staining with horse anti-rabbit-HRP (Vector Laboratories), sections were
developed for 90–120 s with SG detection solution (Vector Laboratories).
Slides were mounted using DPX (Fisher Chemical). Sections were
photographed at × 20 magniﬁcation using an EVOS XL Core Microscope
(Thermo Fisher Scientiﬁc, Peterborough, UK).
Quantiﬁcation of CD3 staining
The whole tumor area was photographed at × 20 magniﬁcation. Five
sequentially numbered ﬁelds of view (FOV) were analyzed per tumor. Where
5–6 FOV were taken, images 1–5 were analyzed; for 7–8 FOV, images 1, 3–5, 7
were analyzed; for 9 FOV, images 1, 3, 5, 7 and 9 were analyzed. Images were
analyzed using the Fiji version of ImageJ. The scale was set to 3.4 pixels= 1 μm
(based on image scale bar). Non-speciﬁc staining was subtracted using
Background Correction, and the images were separated into FastRed, FastBlue
and DAB using Color Deconvolution. The FastBlue image was used to analyze
CD3. Minimum image threshold was set at 87, and maximum image threshold
was set at 173–210. Percent area was analyzed and plotted. In cases where the
tumor section did not cover the whole FOV, the blank area was subtracted
before analysis. Six tumors were analyzed per treatment group.
Statistics and ﬁgures
Statistical analyses were performed in Prism 5 (GraphPad Software Inc, La Jolla,
CA, USA). Figures were prepared using FlowJo software (TreeStar Inc, Ashland,
OR, USA), Powerpoint (Microsoft, Reading, UK) and Prism 5 (GraphPad
Software Inc.). Mean values are presented with s.e.m.
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